Guangzhou, China
YSB Inc., founded in 2015, is recognized as China's largest pharmaceutical digital service platform, focusing on empowering out-of-hospital pharmaceutical market participants through digitalization. This includes extensive collaboration with pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions.
By leveraging digital platforms, YSB Inc. promotes the safe and efficient delivery of pharmaceutical products and services, aiming to offer a transparent and fair pricing model. The company plays a critical role in optimizing the medical and health ecosystem by utilizing its substantial data capabilities to enhance its business model.
Achieving a CAGR of 38.6% from 2020 to 2022, YSB's total GMV reached RMB37.8 billion in 2022, the highest in its sector. The platform covers 379,000 pharmacies and 211,000 primary healthcare institutions, with an average of 353,000 monthly active buyers, marking it as the largest digital pharmaceutical network in China.
In June 2021, YSB Inc. raised a $270.00M Series E investment from investors like Green Pine Capital Partners, Baidu, SFUND, and Pearl River Investment, underlining substantial investor confidence in its growth potential.
